ArticleDrug and alcohol dependence2021
Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.
Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study.Preventive medicine · 2024Trial
- Customizing and fine-tuning opioid overdose machine learning models for community-specific dashboards.Journal of big data · 2026Article
- Geographic Access to Mental Health Facilities for People with Disabilities.The journal of mental health policy and economics · 2026Article
- Public transit and methadone - Spatial analyses of opioid treatment program access in Greater Boston, 2020-2022.Preventive medicine reports · 2025Article
- Justice Core: An Innovative Response to Incarceration During Pregnancy in North Carolina.Journal of correctional health care : the official journal of the National Commission on Correctional Health Care · 2025Article
- Opioid Use Disorder Cascade of Care Among People Who Experienced Perinatal Incarceration: A Qualitative Study.Substance use & addiction journal · 2025Article
- Buprenorphine prescribing practices for older adults in 2019 and 2020.Journal of the American Geriatrics Society · 2025Observational
- Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study.Substance use & addiction journal · 2025Observational
- The impact of buprenorphine prescriber data on geospatial access to treatment in HEALing Communities Study communities, 2022.Journal of substance use and addiction treatment · 2025Article
- Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs.JAMA network open · 2025Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Addiction science & clinical practice · 2025Article
- Emerging neuromodulation treatments for opioid and stimulant use disorders.Frontiers in human neuroscience · 2025Review
- Exploring Opioid Prescription Patterns and Overdose Rates in South Carolina (2017-2021): Insights into Rising Deaths in High-Risk Areas.Healthcare (Basel, Switzerland) · 2024Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Research square · 2024Article
- Trends in Geographic Proximity to Substance Use Disorder Treatment.American journal of preventive medicine · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States.Drug and alcohol dependence reports · 2023Article
- Patterns in Geographic Distribution of Substance Use Disorder Treatment Facilities in the US and Accepted Forms of Payment From 2010 to 2021.JAMA network open · 2022Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUnderstanding whether individuals have geographic accessibility to a substance use disorder treatment facility and a treatment facility that offers medication treatment for opioid use disorder (MOUD) can inform efforts to address the ongoing opioid crisis.
methodsWe used data from the National Directory of Drug and Alcohol Abuse Treatment Programs. First, we calculate the national share of treatment facilities that offer one type of MOUD or all forms of MOUD using a novel dataset of providers. Second, we quantify the share of counties with a treatment facility offering at least one type of MOUD. Finally, we calculate the share of the national population residing within a 10-mile radius of a treatment facility.
resultsThe share of counties with a treatment facility offering a MOUD as a form of treatment rose from 30% to 45% from 2014 to 2020 while the share of counties with facilities offering all three forms of MOUD increased from 4% to 9%. Over 83% of the population lives within 10 miles of a facility offering MOUD treatment, and 42% of the population have a treatment facility that offers all three forms of MOUD within a 10-mile radius. Much of the difference between the county- and population-based measures is explained by more population dense areas having higher rates of facilities providing MOUD.
conclusionsWhile the share of facilities within a county offering a MOUD is relatively small, the share of the population within 10 miles of such a facility is higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.